HC Wainwright & Co. reiterated coverage on NeuBase Therapeutics with a new price target

6/1/21 6:41:11 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

HC Wainwright & Co. reiterated coverage of NeuBase Therapeutics with a rating of Buy and set a new price target of $15.00 from $18.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NBSE

Date	Price Target	Rating	Analyst